

Joo Agostinho Machado-Neto

List of Publications by Citations

Source:

<https://exaly.com/author-pdf/3802400/joao-agostinho-machado-neto-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

88

papers

835

citations

17

h-index

25

g-index

99

ext. papers

1,062

ext. citations

3.9

avg, IF

4.03

L-index

#	Paper	IF	Citations
88	Loss of long noncoding RNA FOXF1-AS1 regulates epithelial-mesenchymal transition, stemness and metastasis of non-small cell lung cancer cells. <i>Oncotarget</i> , 2016 , 7, 68339-68349	3.3	54
87	ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2013 , 1832, 365-74	6.9	39
86	Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. <i>Leukemia Research</i> , 2014 , 38, 1245-51	2.7	38
85	ARHGAP21 protein, a new partner of β tubulin involved in cell-cell adhesion formation and essential for epithelial-mesenchymal transition. <i>Journal of Biological Chemistry</i> , 2013 , 288, 2179-89	5.4	38
84	ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells. <i>Experimental Cell Research</i> , 2014 , 324, 137-45	4.2	37
83	Hydroxyurea is associated with reductions in hypercoagulability markers in sickle cell anemia. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1967-70	15.4	33
82	FMNL1 promotes proliferation and migration of leukemia cells. <i>Journal of Leukocyte Biology</i> , 2013 , 94, 503-12	6.5	32
81	Stathmin 1 in normal and malignant hematopoiesis. <i>BMB Reports</i> , 2014 , 47, 660-5	5.5	30
80	Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells. <i>Leukemia Research</i> , 2014 , 38, 251-7	2.7	25
79	Elevated hypercoagulability markers in hemoglobin SC disease. <i>Haematologica</i> , 2015 , 100, 466-71	6.6	22
78	Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2011 , 1813, 1404-1419	4.9	22
77	ANKHD1 regulates cell cycle progression and proliferation in multiple myeloma cells. <i>FEBS Letters</i> , 2012 , 586, 4311-8	3.8	20
76	De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes. <i>Scientific Reports</i> , 2017 , 7, 40707	4.9	19
75	IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells. <i>Cancer Letters</i> , 2019 , 456, 59-68	9.9	18
74	Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017 , 1863, 450-461	6.9	18
73	ANKHD1 represses p21 (WAF1/CIP1) promoter and promotes multiple myeloma cell growth. <i>European Journal of Cancer</i> , 2015 , 51, 252-9	7.5	18
72	Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia. <i>European Journal of Cancer</i> , 2015 , 51, 2076-85	7.5	17

71	ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015 , 1853, 583-93	4.9	17
70	Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2015 , 94, 413-8	3.8	17
69	Serine peptidase inhibitor Kunitz type 2 (SPINT2) in cancer development and progression. <i>Biomedicine and Pharmacotherapy</i> , 2018 , 101, 278-286	7.5	16
68	Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells. <i>Oncotarget</i> , 2015 , 6, 29573-84	3.3	16
67	NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2-positive myeloproliferative neoplasm cells. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 5	21	15
66	Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients. <i>Leukemia Research</i> , 2012 , 36, 1300-3	2.7	15
65	CATS (FAM64A) abnormal expression reduces clonogenicity of hematopoietic cells. <i>Oncotarget</i> , 2016 , 7, 68385-68396	3.3	14
64	Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome. <i>Journal of Clinical Pathology</i> , 2017 , 70, 435-442	3.9	13
63	BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine. <i>Haematologica</i> , 2016 , 101, e445-e448	6.6	13
62	IL10 inversely correlates with the percentage of CD8+ cells in MDS patients. <i>Leukemia Research</i> , 2013 , 37, 541-6	2.7	13
61	IRS1/βCatenin Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells. <i>Journal of Cellular Biochemistry</i> , 2017 , 118, 1774-1781	4.7	12
60	IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms. <i>Oncotarget</i> , 2016 , 7, 6948-59	3.3	12
59	Insulin Substrate Receptor (IRS) proteins in normal and malignant hematopoiesis. <i>Clinics</i> , 2018 , 73, e5662.3	2.3	12
58	Metformin exerts multitarget antileukemia activity in JAK2-positive myeloproliferative neoplasms. <i>Cell Death and Disease</i> , 2018 , 9, 311	9.8	11
57	Reversine triggers mitotic catastrophe and apoptosis in K562 cells. <i>Leukemia Research</i> , 2016 , 48, 26-31	2.7	11
56	Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms. <i>Diagnostic Pathology</i> , 2016 , 11, 28	3	10
55	Downregulation of IRS2 in myelodysplastic syndrome: a possible role in impaired hematopoietic cell differentiation. <i>Leukemia Research</i> , 2012 , 36, 931-5	2.7	9
54	DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy. <i>Cancer Genetics</i> , 2021 , 252-253, 6-24	2.3	9

53	Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015 , 1853, 388-95	4.9	8
52	Reversine exhibits antineoplastic activity in JAK2-positive myeloproliferative neoplasms. <i>Scientific Reports</i> , 2019 , 9, 9895	4.9	8
51	YAP1 expression in myelodysplastic syndromes and acute leukemias. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2413-5	1.9	8
50	Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion. <i>Journal of Cellular and Molecular Medicine</i> , 2019 , 23, 1562-1571 ^{5.6}	5.6	7
49	Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells. <i>Heliyon</i> , 2017 , 3, e00405	3.6	6
48	PIP4K2A and PIP4K2C transcript levels are associated with cytogenetic risk and survival outcomes in acute myeloid leukemia. <i>Cancer Genetics</i> , 2019 , 233-234, 56-66	2.3	5
47	Differential profile of PIP4K2A expression in hematological malignancies. <i>Blood Cells, Molecules, and Diseases</i> , 2015 , 55, 228-35	2.1	5
46	Serine protease inhibitor kunitz-type 2 is downregulated in myelodysplastic syndromes and modulates cell-cell adhesion. <i>Stem Cells and Development</i> , 2014 , 23, 1109-20	4.4	5
45	Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2 cells. <i>Investigational New Drugs</i> , 2020 , 38, 733-745	4.3	5
44	Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours. <i>Investigational New Drugs</i> , 2020 , 38, 899-908	4.3	5
43	Pradimicin-IRD exhibits antineoplastic effects by inducing DNA damage in colon cancer cells. <i>Biochemical Pharmacology</i> , 2019 , 168, 38-47	6	4
42	Clinical features of JAK2V617F- or CALR-mutated essential thrombocythemia and primary myelofibrosis. <i>Blood Cells, Molecules, and Diseases</i> , 2016 , 60, 74-7	2.1	4
41	Lack of association between MDM2 SNP309 and TP53 Arg72Pro polymorphisms with clinical outcomes in myelodysplastic syndrome. <i>Neoplasma</i> , 2012 , 59, 530-5	3.3	4
40	The U2AF homology motif kinase 1 (UHMK1) is upregulated upon hematopoietic cell differentiation. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018 , 1864, 959-966	6.9	3
39	Gene expression analysis of the Brazilian type of hereditary persistence of fetal hemoglobin: identification of genes that could be related to HbF activation. <i>Hemoglobin</i> , 2013 , 37, 516-35	0.6	3
38	Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. <i>Clinics</i> , 2011 , 66, 793-9	2.3	3
37	Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021 , 35, 116085	3.4	3
36	Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia. <i>Cellular Oncology (Dordrecht)</i> , 2021 , 44, 1105-1117	7.2	3

35	Microemulsion for Prolonged Release of Fenretinide in the Mammary Tissue and Prevention of Breast Cancer Development. <i>Molecular Pharmaceutics</i> , 2021 , 18, 3401-3417	5.6	3
34	Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2015 , 37, 211-4		2
33	PIPKIII β s widely expressed in hematopoietic-derived cells and may play a role in the expression of alpha- and gamma-globins in K562 cells. <i>Molecular and Cellular Biochemistry</i> , 2014 , 393, 145-53	4.2	2
32	Effect of FKBP12-Derived Intracellular Peptides on Rapamycin-Induced FKBP-FRB Interaction and Autophagy.. <i>Cells</i> , 2022 , 11,	7.9	2
31	Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia. <i>Cellular Oncology (Dordrecht)</i> , 2020 , 43, 1191-1201	7.2	2
30	Synthetic cyclopenta[b]indoles exhibit antineoplastic activity by targeting microtubule dynamics in acute myeloid leukemia cells. <i>European Journal of Pharmacology</i> , 2021 , 894, 173853	5.3	2
29	Reactive oxygen species overload promotes apoptosis in JAK2V617F-positive cell lines. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016 , 38, 179-81		2
28	Effects of RhoA and RhoC upon the sensitivity of prostate cancer cells to glutamine deprivation. <i>Small GTPases</i> , 2021 , 12, 20-26	2.7	2
27	NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. <i>Investigational New Drugs</i> , 2021 , 39, 736-746	4.3	2
26	AD80, a multikinase inhibitor, exhibits antineoplastic effects in acute leukemia cellular models targeting the PI3K/STMN1 axis. <i>Investigational New Drugs</i> , 2021 , 39, 1139-1149	4.3	2
25	Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival. <i>Applied Cancer Research</i> , 2018 , 38,	1.6	1
24	Acute myeloid leukemia with e1a2 BCR-ABL1 fusion gene: two cases with peculiar molecular and clinical presentations. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017 , 39, 379-384		1
23	Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. <i>Cancer Science</i> , 2021 ,	6.9	1
22	Emerging functions for ANKHD1 in cancer-related signaling pathways and cellular processes. <i>BMB Reports</i> , 2020 , 53, 413-418	5.5	1
21	Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 , 44, 124-124	1.6	1
20	Targeting glioma cells by antineoplastic activity of reversine. <i>Oncology Letters</i> , 2021 , 22, 610	2.6	1
19	Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016 , 38, 368-370		1
18	Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms. <i>Hematology, Transfusion and Cell Therapy</i> , 2020 , 42, 238-244	1.6	1

17	IRS2 (insulin receptor substrate 2). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2018 ,	2.3	1
16	Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas. <i>Molecules</i> , 2021 , 26,	4.8	1
15	Exploring redox vulnerabilities in JAK2-positive cellular models. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 , 43, 430-436	1.6	0
14	Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells. <i>Toxicology in Vitro</i> , 2021 , 76, 105207	3.6	0
13	Effects of trabectedin in the zebrafish <i>Danio rerio</i> : from cells to larvae. <i>Environmental Advances</i> , 2022 , 8, 100208	3.5	0
12	NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells.. <i>Investigational New Drugs</i> , 2022 , 1	4.3	0
11	Stathmin 1 expression in plasma cell neoplasms. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017 , 39, 183-185		
10	IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. <i>Hematology, Transfusion and Cell Therapy</i> , 2018 , 40, 92-95	1.6	
9	Irs1S57X Heterozygous Mutant Mice Display Normal Hematopoiesis and Phenotypic Features, While Homozygous Knockout Exhibit High Fetal or Postnatal Lethality. <i>Blood</i> , 2020 , 136, 33-34	2.2	
8	STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. <i>Investigational New Drugs</i> , 2021 , 1	4.3	
7	Phenformin increases early hematopoietic progenitors in the Jak2 murine model.. <i>Investigational New Drugs</i> , 2022 , 1	4.3	
6	Expression of transforming growth factor β pathway components in chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.. <i>Transplant Immunology</i> , 2021 , 70, 101514	1.7	
5	IGF1R-IRS1/2 Signaling Pathway Is a Potential Target for FLT3-Mutated Acute Myeloid Leukemia. <i>Blood</i> , 2019 , 134, 2689-2689	2.2	
4	Proteolytic processing in autophagy 2022 , 81-91		
3	Stathmin 1, a therapeutic target in esophageal carcinoma?. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014 , 15, 6461-2	1.7	
2	PTK2 and PTPN11 expression in myelodysplastic syndromes. <i>Clinics</i> , 2013 , 68, 1371-5	2.3	
1	Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2 driven cells.. <i>Toxicology in Vitro</i> , 2022 , 105384	3.6	